FindTrial
Sign In

Addition of oral thalidomide to standard antitubercular regimen for initial 2 months improves the outcome in patients of tubercular meningitis as compared to standard therapy alone.

Thalidomide As An Add On Treatment In The Intensive Phase Of Tuberculous Meningitis â?? An Open Label Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027438
Enrollment
44
Registered
2020-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A170- Tuberculous meningitis

Interventions

Intervention1: Thalidomide, anti tubercular drugs, steroid: Thalidomide will be given as an add on treatment along with ATT and steroid. Oral Thalidomide 100 mg BD one hour after food for one month an

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed new cases of tuberculous meningitis using clinical, CSF and radiological finding. 2.Within one month of starting anti tubercular treatment. 3.Willing to participate in study by signing informed consent. 4. Age 18 year or older of both sexes.

Exclusion criteria

Exclusion criteria: 1.Confirmed meningitis other than TB 2.Pregnancy. 3.Pre-existing neuropathy.

Design outcomes

Primary

MeasureTime frame
Improvement in disability of 2 by Barthel index scoring (at 3 month).Timepoint: 3 months.—

Secondary

MeasureTime frame
Drug related adverse effects, Change in CSF cytokine level (TNF â??alfa and IL-1)Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Mukesh Kumar

AIIMS Bhubaneswar

bhoisanjeev@gmail.com9919787978

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026